Trial Profile
A Phase 1 Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 (Part 1) and a Multiple Dose, Placebo-controlled Exploratory Safety, Pharmacokinetic and Pharmacodynamic Study in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease (Part 2)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Nov 2021
Price :
$35
*
At a glance
- Drugs ASP 8232 (Primary)
- Indications Eye disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma BV
- 22 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 10 Nov 2014 Planned End Date changed from 1 Sep 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov
- 10 Nov 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov